Source: Medthority

SOBI: EC Validates Aspaveli Extension

European Commission validates Aspaveli for C3G and IC-MPGN treatment. Sobi and Apellis lead the way.

Read full article »

SOBI's Competitors | SOBI's News | SOBI's Financials

Followers on Owler

Annual Revenue

$1.0-5.0B

Employees

1.0-5.0K

President & CEO

Guido Oelkers

CEO Approval Rating

48/100

SOBI is a Sweden-based biopharmaceutical company that discovers and develops novel therapies for the treatment of diseases such as hemophilia and cancer.